Bioqual (BIOQ) Akcija Cena
Bioqual Cena
Ieņēmumi auga par 4,1 % gadā pēdējos 22 gados līdz 39,95 M USD. Peļņa uz akciju samazinājās par 1,7 % gadā pēdējos 20 gados. Bioqual neto marža tagad ir -10,4 %, samazinājusies no 8,0 % pirms dažiem gadiem. Bioqual pašlaik piedāvā dividenžu ienesīgumu ap 1,61 %. Izmaksas koeficients ir ap 54 % no peļņas. Dividendes auga par 8,3 % gadā pēdējos 19 gados.
Bioqual akcijas cena
Iegūstiet šos datus caur Eulerpool API
100 000 pieprasījumu/mēn. bez maksas · bez kartes
Bioqual biznesa modelis un akciju analīze
Bieži uzdotie jautājumi par Bioqual akciju
The business model of Bioqual Inc is to provide contract research services to biotechnology and pharmaceutical companies, government agencies, and academic institutions. Bioqual specializes in preclinical and clinical research, including animal model development, in vitro testing, and regulatory compliance. Through collaboration with clients, Bioqual aims to advance the development of drugs, vaccines, and therapeutics, ultimately contributing to the improvement of human and animal health. With its expertise and state-of-the-art facilities, Bioqual Inc has established itself as a trusted partner in the biomedical research industry.
Bioqual Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Bioqual Inc in the market include Company A, Company B, and Company C. These companies operate in the same industry and offer similar products and services to Bioqual Inc. Their competitive presence challenges Bioqual Inc's market position and drives innovation within the industry. Maintaining a competitive edge is crucial for Bioqual Inc to attract and retain customers, expand its market share, and achieve long-term success. As Bioqual Inc continues to navigate its way in the market, it recognizes the importance of monitoring and adapting to the strategies and offerings of its key competitors.
Bioqual Inc. is a reputable company with a rich history and background. Established in [year], Bioqual Inc. has been a leading player in the [industry] sector. The company specializes in [specific products/services] and has built a strong reputation for its commitment to innovation, quality, and customer satisfaction. With a team of experienced professionals and state-of-the-art facilities, Bioqual Inc. has consistently delivered outstanding results and garnered recognition for its contributions to [industry]. Over the years, Bioqual Inc. has expanded its presence globally and continues to be a trusted name in the [industry] market, providing sustainable solutions and driving advancements in [industry].
Bioqual Inc has achieved several significant milestones over the years. The company has successfully gained recognition as a leading biomedical research organization, specializing in preclinical and clinical testing services. Notably, Bioqual Inc has garnered a strong reputation for its contributions to drug development, infectious disease research, and vaccine testing. The company has also established numerous strategic partnerships with pharmaceutical and biotech companies, academia, and government agencies. Furthermore, Bioqual Inc has consistently demonstrated exceptional scientific expertise, state-of-the-art facilities, and a commitment to quality, making it a trusted name in the industry.
Bioqual Inc is primarily present in the United States.
Bioqual Inc represents a commitment to excellence in the field of biomedical research. With a strong emphasis on animal modeling and preclinical testing services, Bioqual is dedicated to paving the way for breakthrough discoveries in healthcare and life sciences. The company's corporate philosophy revolves around comprehensive expertise, innovative solutions, and ensuring the highest standards of animal welfare. By providing state-of-the-art facilities and a team of skilled professionals, Bioqual strives to support scientific advancements and contribute to the development of novel therapies and vaccines. With a focus on quality, reliability, and integrity, Bioqual Inc is trusted by leading pharmaceutical and biotechnology companies worldwide.
Pēc pašreizējā kursa Bioqual akcija maksā 27,78 EUR (31,00 USD).
Bioqual Inc is a US-based company specializing in providing research services and products for the life sciences, pharmaceuticals, and biotechnology industries. The company was founded in 1981 and has been offering innovative solutions to its customers since then.
apgrozījums Bioqual ir 39,95 M USD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.
peļņa Bioqual ir -4,17 M USD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.
Bioqual cenas un peļņas rādītājs (P/E) pašlaik ir -6,65. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt Bioqual akcijas vērtību.
Bioqual cenas un apgrozījuma rādītājs (P/S) pašlaik ir 0,69. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā Bioqual akcijas vērtības mērs.
Bioqual Eulerpool kvalitātes rādītājs ir 1/10.
Bioqual ISIN ir US09065J1016. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.
Bioqual tikeris ir BIOQ. Tikeris tiek izmantots Bioqual akciju tirdzniecībai biržā.
Bioqual akcija
Bioqual Salīdzināmo uzņēmumu grupa
Bioqual FIGI
Visi Bioqual fundamentālie rādītāji un padziļinātā analīze
Mūsu akciju analīze par Bioqual ietver svarīgus finanšu rādītājus, piemēram, apgrozījumu, peļņu, P/E rādītāju, P/S rādītāju, EBIT, kā arī informāciju par dividendēm. Turklāt mēs aplūkojam aspektus kā akcijas, tirgus kapitalizāciju, parādus, pašu kapitālu un saistības no Bioqual. Ja meklējat sīkāku informāciju par šīm tēmām, piedāvājam detalizētas analīzes mūsu apakšlapās: